The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.
 
William Joseph Chapin
No Relationships to Disclose
 
Wei-Ting Hwang
Employment - Janssen (I)
Research Funding - Novartis; Tmunity Therapeutics, Inc.
 
Thomas Benjamin Karasic
Honoraria - Exelixis; Incyte; Pfizer
Research Funding - Bristol-Myers Squibb; Celgene; H3 Biomedicine; Lilly; Sirtex Medical; Syndax; Taiho Pharmaceutical; Tempest Therapeutics
 
Anne Marie McCarthy
No Relationships to Disclose
 
David Edward Kaplan
Honoraria - Bayer
Consulting or Advisory Role - Exelixis
Research Funding - Bayer (Inst); Gilead Sciences (Inst); Inovio Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Glypican-3 Chimeric Antigen Receptor (Inst)